Th e fi rst case report describing atypical fractures of the femur was published in 2005 and reported on nine adults receiving bisphosphonate treatment [1] . Since that time, the number of case reports has increased markedly, and the existence of atypical femoral fractures (AFFs) is now widely accepted. Th e incidence remains low, but substantial mortality is associated with these fractures. Little is known regarding their etiology and mechanism. Th e measurable factors and individual characteristics contribut ing to AFF development in particular individuals require further investigation given the large number of postmenopausal women on these agents [2] .
In 2009, the American Society of Bone and Mineral Research (ASBMR) appointed a task force to summarize the current state of knowledge and address key questions about AFFs. Based on a comprehensive literature review and the experiences of clinical experts on the task force, a case defi nition was generated ( Table 1 of [3] ). To defi ne a fracture as an AFF, the following fi ve major features must be present ( Figure 1 ): 1) location along the femur distal to the lesser trochanter and proximal to the supercondylar fl are; 2) minimal or no trauma at fracture; 3) transverse or short oblique fracture confi guration; 4) lack of comminu tion; and 5) complete fractures extend through both cortices and may be associated with a medial 'spike' or incomplete fractures involve only the lateral cortex. An additional seven 'minor features' are often reported but are not required for classifi cation as an AFF, including a lateral periosteal reaction, cortical thickening, prodromal symptoms and bilateral incidence. Combined these criteria suggest contributing biomechanical factors include whole bone geometry and material properties [4, 5] , as described below.
While no direct causation has been established, AFFs are often associated with long-term bisphosphonate treatment. In the 310 case reports examined by the ASBMR task force, 291 of the published reports (94%) identifi ed bisphosphonate use as a comorbidity, with a mean treatment duration of 7 years. While this association is present in case reports, a similar connection has not been established in the phase III clinical trial data ( [6] and see
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Larger population-based studies have drawn conclusions both for and against the association of AFFs with bisphosphonate use. In a Danish cohort study based on examining only medical records, not radiographs, the risk of hip and subtrochanteric or femoral shaft fractures was increased in bisphosphonate-treated (alendronate) patients [8] . However, individuals with greater cumulative bisphosphonate doses did not have greater risk of AFFs than individuals exposed to smaller doses, leading the authors to conclude that osteoporosis could be the underlying cause of the fractures. Risk for subtrochanteric or femoral shaft fractures was associated with bisphosphonate treatment for more than 5 years in a case control study of a large population-based cohort of elderly women (aged 68 years or older at initiation of bisphosphonates) [9] . Th e risk of typical osteoporotic femoral neck or intertrochanteric fractures was reduced in the same population with long-term bisphosphonate treatment, as would be expected; 716 AFF patients were included, with 3,580 matched controls. All diagnoses were medical record-based; no radiographs were examined in this study.
Bisphosphonates
Bisphosphonates are used to treat osteoporosis by targeting bone resorption and reduce fracture rates in the spine by 40 to 50%. Two primary mechanisms contribute to their effi cacy: affi nity for binding to bone mineral and inhibition of osteoclast function [10] . Th e coupling of bone resorption and formation in remodeling leads to an overall reduction in bone turnover with bisphosphonate treatment. Quantitatively, reductions in bone turnover do not map directly to reduced fracture risk, nor do increases in bone mass fully explain reductions in fracture incidence with bisphosphonate treatment.
Bisphosphonates are chemically stable analogues of pyrophosphate compounds, fi rst introduced into clinical practice 50 years ago in 1962 [11] . All bisphosphonates contain non-hydrolysable P-C-P bonds. Th ey can be divided into diff erent classes based on structure: those with aliphatic chains (etidronate or clodronate) and the N-containing bisphosphonates; those containing nitrogen as part of the aliphatic chain (neridronate, alendronate and ibandronate); or those containing one or more fi ve-or six-membered rings (risedronate, zolendronate and mindronate). Th e structures and functions of the major bisphosphonates in clinical use were reviewed recently [12] . Th e mechanisms of action of the fi rst generation, aliphatic chain bisphosphonates and the Ncontaining bisphosphonates are very diff erent. Both bind with high affi nity to bone mineral (hydroxyapatite) [13] , but fi rst generation bisphosphonates, such as etidronate and clodronate, bind directly to analogues of ATP forming ATP-P-C-P complexes, preventing ATP hydrolysis and leading to cell death [11, 14] . Th e N-containing bisphosphonates, in contrast, inhibit farensyl pyrophosphate synthase activity, preventing the prenyla tion of proteins required for cell function and survival and leading to premature apoptosis in the exposed cells [11] . Since the osteoclast is the cell exposed to the majority of the bisphosphonates retained in bone, bisphosphonates result in osteoclast cell death, and hence inhibit bone remodeling. Th e loss of osteoclasts, in turn, can aff ect osteoblast activity as these processes are coupled. Osteoclasts can be rescued from the apoptosis-inducing eff ects of the bisphosphonates by inducing expression of anti-apoptotic factors [14] . Osteoblasts and osteocytes can also become apoptotic via a similar mechanism, depend ing on the bisphosphonate used, which would also impact new bone formation [15] .
Zolendronate is the bisphosphonate with the greatest in vitro affi nity for hydroxyapatite, followed by pamidronate, alendronate, ibandronate, risedronate, etidronate and clondronate, with clondronate having the least affi nity [13] . Each of these compounds has been used in clinical trials to treat osteoporosis [16] and non-skeletal diseases [17] . Osteoporosis is a disease characterized by increased fracture risk as a result of an imbalance between bone formation (by osteoblasts and osteocytes) and bone resorption (by osteoclasts). Th e outcome assessments most frequently used to judge therapeutic effi cacy are: changes in bone mineral density (BMD; or bone quantity as assessed by dual energy X-ray absorptiometry (DXA)); bone turnover markers, such as N-and Ccollagen telopeptide cross-link breakdown products, bone-specifi c alkaline phosphatase, osteocalcin or hydroxyproline; dynamic histomorphometric measures of mineral deposition rate (which require a biopsy); and fracture incidence in large clinical studies.
Generally, bone turnover markers decrease and BMD increases in large clinical trials but diff erences exist by specifi c agent, skeletal site and individual response. In clinical trials, BMD in patients treated with bisphosphonates increased at 1 and 3 years [16] . In general, changes are greater at the spine than in the hip or femoral neck. BMD increases due to fi lling in of remodeling space and continued secondary mineralization of pre-existing bone tissue. To complicate the story, diff erent drugs act at diff erent rates (for example, zoledronic acid is reported to have more rapid eff ects than alendronate [16] ), but, on average, bisphosphonate therapies eff ectively reduce bone turnover. Overall, bisphosphonates can improve bone properties and reduce fracture risk [6, [18] [19] [20] as evident from improved histomorphometric parameters [21] , decreased changes in bone turnover markers [22] , and increased BMD [23] .
Quantitatively, reductions in bone turnover do not map directly to reduced fracture risk, nor do increases in bone mass fully explain reductions in fracture incidence with bisphosphonate treatment. Antiresorptive treatments produce modest increases in areal bone mineral density, ranging from 0 to 8%, yet reduce fracture risk by 30 to 50% [24] [25] [26] . Th is disproportionate decrease in fracture incidence [27] suggests altered tissue material characteristics are likely a contributing factor to the effi cacy of these therapies in osteoporotic patients. By preventing trabecular plate perforation, bisphosphonates may prevent the cancellous microarchitectural deterioration that leads to osteoporotic fractures.
Despite these positive eff ects on fracture risk, many questions remain concerning bisphosphonate use. Some issues are obviously related to patient compliance [16] , but the more relevant ones concern prescribing of bisphosphonates: who are appropriate patients and how long should treatment be continued. Is a 'bone holiday' , in which bisphosphonate treatment is suspended for 5 or 10 years, a good recommendation? Are other drugs as eff ective in reducing fracture risk? It is beyond the scope of this review and of the basic science authors to make recommendations in response to these questions, but a few facts can be pointed out. In a meta-analysis of patients who discontinued bisphosphonates for 5 years after 5 years of treatment, with only three eligible studies, fracture risk was not diff erent between the two groups [28] . Th is result may refl ect the retention of the bisphosphonates within the bone due to their high affi nity for hydroxyapatite. In fact, in patients on 10 mg/day of alendronate for 5 years the drug exposure remains at 25% of the original dose in the 5 years after treatment is stopped [29] . Because AFFs may be associated with 'prolonged' bisphosphonate use, we will consider the known eff ects of short-and long-term bisphosphonate treatments on bone mechanics and bone quality. Other reported complications of bisphosphonate use are reviewed elsewhere [30] .
Mechanics
From a mechanics perspective, the fi ve major features outlined by the ASBMR task force to defi ne AFFs provide insights into potential mechanisms contributing to fracture [3] . Minimal or no trauma, a required feature, suggests that AFFs result from repetitive loading (fatigue fracture) rather than a single overload (traumatic fracture). Th is conclusion is further confi rmed by the frequent presence of a periosteal reaction and prodromal symptoms, both minor features. Characteristics of long bones known to contribute to the development of skeletal stress fractures (fatigue fractures) are whole bone structure and applied loading [31] [32] [33] . Once damage has been initiated, cracks propagate and coalesce to produce structural failure and fracture, a process that depends on cortical cross-sectional geometry and tissue material properties.
Th e frequent bilateral incidence of AFFs, a minor feature, also suggests a strong mechanical etiology associated with individual anatomy. Diff erences in whole bone geometry relative to non-fractured controls, such as the femoral neck shaft angle and femoral curvature [4] , can alter the stresses and strains produced in the cortical diaphysis with loading and may contribute to fracture van der Meulen and Boskey Arthritis Research & Therapy 2012, 14:220 http://arthritis-research.com/content/14/4/220 incidence. Th e existence of whole bone structural diff erences between individuals with and without AFFs needs to be determined and, if present, related to bone tissue level strains and stresses and stress fracture development.
Th e transverse fracture confi guration, another major feature, suggests that the material properties of bone tissue are altered in individuals with AFFs. Th e femur experiences high bending and torsional loads that normally produce oblique or spiral fracture confi gurations due to the applied loading and well-documented mechanical properties of cortical bone [5] . Bone tissue is weaker in tension than compression, and this asymmetry is refl ected in the morphology of the fracture surface. Altered mechanical properties, such as increased tissue brittleness, would further alter fracture morphology. Comorbidities associated with AFFs, such as bisphos phonate therapy, could contribute to such alterations in tissue properties and bone quality.
Limited data are available on the eff ects of bisphosphonate treatment on bone tissue properties, particularly for cortical bone where AFFs occur. Th e majority of preclinical studies examining material properties of cortical tissue were performed in canine models without estrogen defi ciency and using supraphysiological bisphos phonate doses (see review by Allen and Burr [34] ). In addition, more data are available on cancellous bone than on cortical bone, given the osteoporosis emphasis of these treatments. In cortical bone, bisphosphonate treatment generally does not alter bone material strength and stiff ness, but high doses decrease post-yield toughness [35] [36] [37] . Post-yield toughness was reduced 28% with alendronate (1.0 mg/kg) and 51% with risedronate (0.5 mg/kg) in the healthy canine tibia after 1 year [37] , 19% with alendronate in the canine rib after 1 year [38] , and 34% with alendronate in the canine rib after 3 years [36] . However, material property changes were not present in the canine femoral diaphysis after 1 and 3 years of alendronate treatment. Finally, nanomechanical analysis of iliac crest biopsies showed no diff erences in cortical modulus in tissue from AFF patients relative to agematched and young female controls [39] . Th ese data suggest that the tissue elastic behavior is not altered with bisphosphonate treatment but cannot measure toughness or fatigue properties. Considered in terms of fracture mechanics, the transverse fractures seen clinically suggest increased damage and reduced deformation post-yield that lead to a brittle fracture of the femur.
Bone quality
Bisphosphonates increase the quantity or amount of bone (BMD), but tissue quality contributes to fracture risk as well. Bone quality, as reviewed recently [40] , includes properties beyond bone mass that contribute to bone mechanical strength, and hence fracture risk. Th ese properties include bone geometry (the shape and size of bone), architecture (the arrangement of the structures within the bone), collagen maturity (collagen cross-links and advanced glycation products), the presence of microdamage, and the properties of the mineral, including its distribution, composition, orientation, crystal size and perfection. Each of these characteristics correlates to either fracture risk or bone strength, or both.
Cortical geometry
Both whole bone morphology and cross-sectional geometry of the femur determine the mechanical environment in the cortex and can predispose the hip to fracture [4, 41] . Military recruits who present with stress fractures have smaller cross-sectional geometry than those who do not fracture [31] . In addition, bone tissue quality may be linked with whole bone morphology. In a small sample, the cortical tissue of slender male tibiae was more brittle and damage-prone than the cortex of wider bones [33] . In the spine, fracture risk was associated with crosssectional geometry [42] .
Th e ASBMR task force included localized periosteal reaction and generalized cortical diaphyseal thickening as minor features of AFF [3] . Reports of AFF often do not distinguish between cortical thickening and periosteal stress reaction. Increased cortical thickness has been noted with AFF [3, 43] .
Whether bisphosphonates alter cortical geometry is unclear. At corticocancellous sites, the cortical shell thickness and area increases in osteoporotic women with bisphosphonate treatment [44, 45] . For example, risedronate increased the cross-sectional moment of inertia and cross-sectional area of the femur in osteoporotic and osteopenic women and men after 4, 8, and 12 months of treatment [44] . In a recent report, however, cortical thick ness of the femoral diaphysis was not increased with alendronate treatment for at least 5 years when measured by DXA [46] , but DXA has limitations for measuring cortical thickness [47] . Th us, the eff ects of bisphosphonates on cortical architecture remain to be elucidated, and if present, geometric eff ects may also be accompanied by alterations of other tissue properties.
Collagen
Th ree fundamental properties of the collagen network infl uence mechanical properties [48] : the amount of collagen; the fi bril orientation [49] ; and its maturity (post-translational modifi cation of the collagen). Collagen fi brils are formed from triple-helical collagen molecules. With age, the stability of the collagen fi brils increased by forming intra-and inter-fi brillar cross-links. Some cross-links are derived by enzymatic pathways through which collagen lysyl and hydroxylysyl groups form fi ve-and six-membered rings with other amino van der Meulen and Boskey Arthritis Research & Therapy 2012, 14:220 http://arthritis-research.com/content/14/4/220 acids; these enzymatic cross-links may be non-reducible (more stable) or reducible. A second type of cross-link is derived by non-enzymatic glycosylations [50] . Th e presence of both types of cross-links can be determined biochemically or inferred from spectroscopic correlates.
Mechanical properties have been correlated with the number of non-enzymatic glycosylations [50] and enzymatic cross-links [51] . In animal models with chemically altered collagen cross-links and in osteoporotic human specimens higher ratios of non-reducible/reducible cross-links are associated with increased bone stiff ness and strength [52, 53] . In contrast, increased concentration of non-enzymatic cross-links with aging correlated with decreased bone strength [53] .
Bisphosphonates have been reported to increase the amount of non-enzymatic cross-links without changing the number of enzymatic cross-links. Compared to placebo, risedronate retained baseline values of collagen cross-links, measured by infrared imaging, in active bone-forming areas, returning to premenopausal values after 5 years of treatment [54] . In a preclinical healthy canine model, reductions in post-yield toughness of cortical tissue with high doses of bisphosphonates were associated with increased non-enzymatic collagen glycation [37] .
Microdamage
Loading of bone creates damage in the form of cracks. Fracture resistance partially depends on the ability of bone to remodel and repair microscopic cracks or microdamage before they lead to failure. Longer cracks are associated with weaker bone [55] . Reducing bone turnover could aff ect damage repair and damage accumulation, particularly given that AFFs are likely fatigue fractures. Increased crack lengths and density accompanied reductions in post-yield toughness of cortical bone with high dose bisphosphonate treatment [36, 38] . Clinically, however, the number of microcracks and their frequency was low in postmenopausal osteoporotic women and not altered in iliac crest biopsies from women on bisphosphonates relative to untreated control biopsies [56] . Th ese clinical data are for cancellous tissue, however, and data are needed for the cortex. Th e question of whether microcrack initiation and repair is suppressed by bisphosphonates remains open, especially in cortical bone.
Mineralization
Th e amount of mineral present and its alignment, distribution and characteristics, such as chemical compo sition, and crystal size and orientation, contribute to the mechanical function of the mineralized tissue and fracture risk, and may in part help explain the AFF phenotype. In mice of diff erent ages, signifi cant positive correlations were observed between the elastic modulus and the compositional properties determined by infrared imaging, including mineral/matrix ratio and crystallinity [57] . In multiple linear regressions of mineral properties from 52 individuals with and without fracture, increases in three parameters were signifi cantly associated with increased fracture risk: cortical and cancellous collagen maturity; cortical mineral/matrix ratio; and cancellous crystallinity [58] .
Bisphosphonate treatment has multiple eff ects on mineral properties. Risedronate for 3 and 5 years maintained material properties in iliac crest biopsies of treated postmenopausal women, while mineral content and crystallinity increased in placebo groups [54] . Th ese matrix material changes were thought to contribute to risedronate's rapid and sustained antifracture effi cacy in osteoporotic patients [54] . Similarly, based on Raman spectroscopic analysis, a study of biopsies from women treated with zolendronate once yearly over a 3-year period showed an increased mineral/matrix ratio compared with placebo and resulted in smaller mineral crystallites that are characteristic of younger bone [59] .
Tissue heterogeneity is reduced with bisphosphonate treatment as measured by Fourier transform infrared spectroscopy imaging. Following short-term treat ment with alendronate, iliac crest biopsies from perimenopausal woman had decreased compositional parameter distributions (heterogeneity) relative to untreated controls [60] . Similar results were found in a normal, non-osteopenic animal model treated with either risedronate or alendronate [61] . In biopsies obtained adjacent to hip fracture site in bisphosphonate-treated women, includ ing some with AFFs, the heterogeneity of the compo sitional parameters also decreased compared to bisphosphonate-naïve women, while the mean property values were similar [49] . Interestingly, the cortical mineral/matrix ratio was 8% greater in tissue from patients with atypical subtrochanteric fractures than that of patients with typical fractures. Th e reduced mineral and matrix heterogeneity may diminish tissue-level tough en ing mechanisms that normally inhibit crack propa gation. Altered tissue mineralization has been impli cated in bisphosphonate treatment [62, 63] and needs to be related to tissue mechanical performance.
Conclusion
Th e concern of whether long-term bisphosphonate use oversuppresses bone turnover contributing to AFF remains open. Th ose patients who suff er AFF appear to have unique compositional characteristics, which could indicate pre-existing qualities prior to the initiation of bisphosphonate therapy or a property that occurs in a limited number of patients as a result of bisphosponate treatment. Th e suggestion of a bisphosphonate holiday in van der Meulen and Boskey Arthritis Research & Therapy 2012, 14:220 http://arthritis-research.com/content/14/4/220 which treatment is stopped for short periods of time to avoid AFF formation is controversial because the successful return to 'normal' remodeling needs to be demonstrated. Retention of bisphosphonates in the bone matrix may result in residual release for more than 7 years [13, 64] .
Evidence is mixed regarding the contribution of oversuppression of bone turnover with bisphosphonate treatment to AFF initiation. Limited histological analyses have been performed on tissue from individuals with AFFs to support the mechanisms suggested above. Severely suppressed bone turnover was evident based on the absence of double fl uorochrome labels in iliac crest biopsies from patients with AFFs [1, 65] . In a case report, tissue from the femur and iliac crest demonstrated increased resorption and decreased formation in a 76-year-old woman with a femoral fracture [66] . In tissue removed at the fracture site during intramedullary nail insertion in a 57-year-old woman, evidence of bone remodeling was present; however, a great number of empty osteocytic lacunae were evident, as was necrotic and damaged tissue at the fracture site [67] . In all cases, the presence of a clear fracture callus and radiolucency at the site of fracture initiation suggests that bone tissue can still be actively formed and resorbed in these individuals, although local demineralization is also a possible mechanism.
In conclusion, insuffi cient evidence exists on the specifi c eff ects of bisphosphonates on cortical bone quality and tissue properties, and their eff ects on the mechanical performance of the skeleton. Based on current knowledge, bisphosphonates remain a safe and eff ective therapy to prevent fractures in osteoporotic individuals. Further investigation into the origin of AFFs is required, along with better methods to detect those few patients at risk for developing this major complication.
